Lundbeck sites | Contact Us |

You are here: Home » About Cipralex » Fast Onset of Action » Cipralex vs. Venlafaxine xr

Cipralex vs. Venlafaxine xr

Earlier sustained remission with Cipralex

Patients in sustained remission (%) (ref.1)

Percentage of patients treated with escitalopram and venlafaxine xr 75–150 mg/day in sustained remission during an 8-week period. A larger proportion of escitalopram-treated patients achieved sustained remission at weeks 2–8 (logistic regression, including factors for treatment, centre and baseline MADRS score). Sustained remission was defined as patients in remission (MADRS≥12) that was maintained until week 8.
ITT; #p<0.05
##p<0.01

As % of patients in remission at week 8 (ref.1)

Plot of number of patients in remission from each treatment group as a percentage of the total number of patients in remission at week 8. Escitalopram-treated patients achieving remission at week 8 achieved sustained remission 6.6 days faster than venlafaxine wr-treated patients. The dotted lines indicate median time to achieve remission.
ANCOVA, p<0.001

Cipralex works faster than Venlafaxine XR

 

  • Cipralex offers earlier response and more patients achieved sustained remission in weeks 2-8 compared with venlafaxine xr.
  • Cipralex treated patients achieved 6,6 days earlier sustained remission than venlafaxine xr treated patients.
  • Furthermore Cipralex has a superior tolerability profile compared with venlafaxine xr and thus possesses a better benefit-risk profile.

References:

1. Montgomery et al. 2004

Last updated: 31.07.2008
Print 

Literature Search
Related key publications
»

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

»

All related key publications (Depression)

»

All related key publications (Anxiety)

[no alt text]
 
Home | Lundbeck sites | Disclaimer | Contact us